Targeting tumor supporting cells: Lipid nanoparticles advance CAR T success in pancreatic cancer

Often diagnosed when surgery is no longer an option, pancreatic cancer is one of the most difficult cancers to treat and has one of the lowest rates of survival among major malignancies. Like many solid tumors, the most common type of pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC), is shielded by the desmoplastic matrix—a dense barrier of connective tissue, structural proteins, and specialized cells called cancer-associated fibroblasts (CAFs)—that also suppresses the immune response.